SI
SI
discoversearch

 Biotech / Medical | Imclone systems (IMCL)


Previous 10 | Next 10 
To: Wes Stevens who wrote (954)9/2/1999 10:45:00 PM
From: QuietWon
   of 2515
 
Anyone notice the set-up by the press? One article quotes McCammant as saying the stock has been held down by a large seller, but that seller is almost finished. Then today, IMCL says they're worth more than any offers.

Gimme a break on the first article - happy to see it, yes, but man o man is Wall Street such the set up.

Now, for anyone interested a couple of similarities of IMCL sitaution to other stocks:

1) FVCX. IMCL had 780 call option contracts bot in one order a week before an Individual Investor article and then about 3-4 weeks later it's on CNBC and it's off to the races. Well, FVCX has over 400 calls @10 bot over past few days...pattern??

2) GBIX. I did an on-site investigation of IMCL in January - stock was $9-10 then. Last Friday was at GBIX's offices in NYC - dispelling the garbage-posts on Yahoo msg board and it confirmed my thoughts of GBIX being significantly undervalued and overlooked.



Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: caly who wrote (946)9/3/1999 12:35:00 PM
From: caly
   of 2515
 
Clinical trial details should anyone be interested:

C225 head and neck cancer:

cancernet.nci.nih.gov

C225 breast cancer:

cancernet.nci.nih.gov

BEC2 melanoma:

cancernet.nci.nih.gov

BEC2 small cell lung cancer:

cancernet.nci.nih.gov

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: caly who wrote (956)9/3/1999 3:53:00 PM
From: Gordon James
   of 2515
 
calypso,

FYI - I believe the C225/breast cancer trial that still shows up on NCI Cancernet is very old info, the trial perhaps never officially completed and seemingly quite inactive. At any rate, doesn't seem to figure much into near-term C225 development plans at this point. Just thought I'd mention that for benefit of any who might see this and think that there was a new C225/breast cancer trial just getting underway...

Cheers,
Gordon

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: Gordon James who wrote (957)9/3/1999 4:03:00 PM
From: caly
   of 2515
 
Thanks for pointing that out, Gordon. I got to those links by going through an "Ongoing Clinical Trials" link from NCI. I assumed they'd be up to date.

I had noticed this on the IMCL website though, and just assumed I had the right trial:

breast cancer a dose-ranging phase Ib/IIa study for patients with metastatic disease in combination with taxol, the study's objectives are to determine the pharmacologic, safety and efficacy profiles of the combination therapy. This study is open to enrollment.

imclone.com

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: caly who wrote (958)9/3/1999 5:49:00 PM
From: Gordon James
   of 2515
 
calypso,

You're probably right that this trial is officially still in progress - I just wanted to point out that it appears to be something along the lines of "dead, just not buried yet", and so nothing to get excited about for people who may have just ran across it. Reason I say this is that the trial was initiated way back in March of 1996, and the "health professional abstract" for the trial on NCI Cancernet indicates that "up to 12 evaluable patients will be studied", but both NCI and ImClone web page show the trial as still open for enrollment. If they haven't gotten 12 patients enrolled in 3.5 years, doesn't look like a trial that's going anywhere. Still possible that they'll complete this trial at some point and announce some results, but I'm not too excited about it given the current status...

Cheers,
Gordon

P.S. Search Recombinant Capital for more info on this trial including press release:
recap.com
See the "health professional abstract" via a link on the NCI page for this trial that calypso provided.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Gordon James who wrote (959)9/3/1999 6:03:00 PM
From: caly
   of 2515
 
Got it. Thanks much, Gordon!

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: caly who wrote (960)9/5/1999 3:36:00 PM
From: JEB
   of 2515
 
(April 14,1999)

"These data in pancreatic cancer models provide further evidence that C225 as a single therapy or in combination with standard therapies can inhibit the growth and spread of a wide variety of cancer cells, including pancreatic cancer cells," stated Samuel D. Waksal, President and CEO of ImClone Systems. "What we have learned from these preclinical studies in a very difficult cancer model is now going to allow us to move forward in clinical trials for pancreatic carcinoma this quarter."

We should be hearing about these clinical trials very soon, ...or has the street already picked up on this.

;-)
JEB

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: JEB who wrote (961)9/5/1999 3:53:00 PM
From: caly
   of 2515
 
Thanks, JEB. If clinical trials are started for pancreatic cancer, that would be great news. Most importantly, I hope C225 is effective against it. Right now, diagnosis of that form of cancer is a death sentence.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: caly who wrote (962)9/6/1999 4:20:00 PM
From: JEB
   of 2515
 
I'd say C225 offers an excellent chance of stopping or eliminating pancreatic cancer:

imclone.com

IMCLONE?S LEAD CANCER THERAPEUTIC, C225, DEMONSTRATES
ANTI-TUMOR ACTIVITY IN PRECLINICAL MODELS OF PANCREATIC CARCINOMA
Philadelphia, PA -- April 14, 1999 -- ImClone Systems Incorporated (Nasdaq: IMCL) announced today findings from two preclinical studies of the company?s lead cancer therapeutic, C225, demonstrating anti-tumor activity in animal models of human pancreatic carcinoma. The findings were presented at the annual meeting of the American Association for Cancer Research (AACR). C225, a monoclonal antibody, is an inhibitor of the epidermal growth factor receptor (EGFr) which is associated with cancer cell growth in a number of solid tumors.
In a poster session on Sunday, researchers in the laboratory of Dr. Robert Radinsky, Assistant Professor of Cell Biology at MD Anderson Cancer Center in collaboration with ImClone scientists, presented data on the use of C225 in combination with the anti-cancer drug gemcitabine in a mouse model of pancreatic cancer. Combined administration of C225 plus gemcitabine caused a 90 percent reduction in pancreatic tumors, compared with a 27 percent response rate using gemcitabine alone. In addition, C225 used alone resulted in significant tumor regression and destruction of liver metastases when compared to treatment with gemcitabine.
Dr. Radinsky?s laboratory also presented data which showed an anti-angiogenic mechanism for C225 treatment in the pancreatic carcinoma model. It was shown that the expression of the angiogenic factors, vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8), were significantly reduced in response to C225 treatment.
In a mini-symposium today, researchers from the laboratory of Dr. Daniel Hicklin at ImClone Systems presented additional findings demonstrating that C225 caused reduction of pancreatic cancer cell proliferation and significantly inhibited growth of established pancreatic tumors compared to untreated controls in a nude mouse model. Pancreatic tumors treated with C225 showed a decrease in tumor cell proliferation and massive tumor necrosis (tissue death).
"These data in pancreatic cancer models provide further evidence that C225 as a single therapy or in combination with standard therapies can inhibit the growth and spread of a wide variety of cancer cells, including pancreatic cancer cells," stated Samuel D. Waksal, President and CEO of ImClone Systems. "What we have learned from these preclinical studies in a very difficult cancer model is now going to allow us to move forward in clinical trials for pancreatic carcinoma this quarter."
ImClone has conducted several Phase Ib/IIa clinical trials using C225 in several cancer indications. In March 1999, the Company initiated a Phase III clinical trial of C225 in patients with advanced squamous cell head and neck cancer.
In addition to C225, ImClone?s other late stage clinical development program is an anti-cancer vaccine, BEC2. In May 1998, ImClone and its corporate partner Merck KGaA initiated a Phase III multinational clinical trial in limited disease small cell lung cancer patients. Also in preclinical development, ImClone is evaluating the therapeutic potential of its anti FLK-1/KDR monoclonal antibody as an anti-angiogenic agent, especially against tumors known to secrete vascular endothelial growth factor.
ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical company developing novel therapeutic products including interventional therapeutics, cancer vaccines and blood cell growth factors for the treatment of cancer and cancer-related disorders.
Except for the historical information contained herein, the matters discussed in this news release may include forward-looking statements. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company?s business, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance of and continuing demand for the Company?s products, the impact of competitive products and pricing, and the Company?s ability to obtain additional financing to support its operations. The Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: caly who wrote (962)9/6/1999 9:35:00 PM
From: QuietWon
   of 2515
 
To: All IMCL Investors ...............>

You may rem in Jan/Feb, I presented comparisons of ENMD to IMCL saying concluding there's a new kid in town - IMCL. IMCL was $9-10 then, now approx $35. Marty and JEB provided some help and kept my sanity. We were all in well before Anthony@Pacific appeared on the scene -- here are some of the posts: Message 11171655

I did several comparisons: IMCL vs ENMD vs ONXX vs MDDM
and fought off all the naysayers putting my research, JEB's, and Marty's down.

I went to the offices of the company which gave greater knowledge and comfort about IMCL. Yes, I pounded the table, b/c I found greater positives than negatives and better than comparable offerings/techniques.

Not gloating - have 2 other co's I believe in very strongly and these 2 co's each have good fundamentals and technicals.

1. FVCX Message 11162726

2. GBIX - I went to their operational office in NYC Fri Aug 27 -- reports of on-site visit:
Part 1: Message 11115421
Part 2: Message 11139265
Part 3: Message 11166791

More to come on GBIX.

These are Nasdaq stocks. There is no bullcrap. There is no ego. These are significantly undervalued/unrecognized, imo. Worth a strong look.

Share Recommend | Keep | Reply | Mark as Last Read
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.